Two Sigma Advisers
RGNX icon

Two Sigma Advisers’s Regenxbio RGNX Stock Holding History

Two Sigma Advisers’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,400
Closed -$697K – 1687
2025
Q4 		$697K Sell
48,400
-21,700
-31% -$270K ﹤0.01% 1658
2025
Q3 		$676K Sell
70,100
-54,800
-44% -$485K ﹤0.01% 1636
2025
Q2 		$1.03M Sell
124,900
-72,100
-37% -$604K ﹤0.01% 1432
2025
Q1 		$1.41M Buy
197,000
+17,000
+9% +$126K ﹤0.01% 1298
2024
Q4 		$1.39M Buy
180,000
+112,000
+165% +$1.05M ﹤0.01% 1298
2024
Q3 		$713K Sell
68,000
-7,900
-10% -$96.3K ﹤0.01% 1557
2024
Q2 		$888K Buy
75,900
+18,700
+33% +$291K ﹤0.01% 1606
2024
Q1 		$1.21M Buy
57,200
+44,600
+354% +$794K ﹤0.01% 1486
2023
Q4 		$226K Buy
+12,600
New +$222K ﹤0.01% 2191
2023
Q2 		– Sell
-10,600
Closed -$200K – 2611
2023
Q1 		$200K Sell
10,600
-2,500
-19% -$55.3K ﹤0.01% 2268
2022
Q4 		$297K Sell
13,100
-8,300
-39% -$188K ﹤0.01% 2075
2022
Q3 		$566K Buy
21,400
+4,100
+24% +$122K ﹤0.01% 1791
2022
Q2 		$427K Buy
17,300
+4,100
+31% +$102K ﹤0.01% 1988
2022
Q1 		$438K Buy
+13,200
New +$367K ﹤0.01% 2049
2021
Q4 		– Sell
-53,000
Closed -$2.22M – 2777
2021
Q3 		$2.22M Buy
53,000
+40,700
+331% +$1.46M 0.01% 1190
2021
Q2 		$478K Sell
12,300
-27,500
-69% -$984K ﹤0.01% 1958
2021
Q1 		$1.36M Buy
+39,800
New +$1.7M ﹤0.01% 1475
2019
Q3 		– Sell
-35,900
Closed -$1.84M – 2366
2019
Q2 		$1.84M Sell
35,900
-53,800
-60% -$2.69M ﹤0.01% 1243
2019
Q1 		$5.14M Sell
89,700
-46,800
-34% -$2.32M 0.01% 832
2018
Q4 		$5.73M Buy
136,500
+2,800
+2% +$164K 0.02% 760
2018
Q3 		$10.1M Buy
133,700
+123,600
+1,224% +$8.91M 0.02% 577
2018
Q2 		$725K Sell
10,100
-8,400
-45% -$401K ﹤0.01% 1755
2018
Q1 		$552K Sell
18,500
-3,576
-16% -$104K ﹤0.01% 1775
2017
Q4 		$734K Buy
+22,076
New +$665K ﹤0.01% 1634

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Advisers's RGNX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 48,400 shares — an estimated $697K sold.

Two Sigma Advisers first reported a position in RGNX in Q4 2017 and held it in 24 quarters. The position peaked at $10.1M in Q3 2018. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 48,400 Regenxbio shares in Q1 2026, an estimated $697K.
  • Two Sigma Advisers first reported a position in Regenxbio in Q4 2017 and held it in 24 quarters.
  • Two Sigma Advisers's Regenxbio position peaked at $10.1M in Q3 2018.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.